GRI Bio (GRI) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
15 Jan, 2026Opening remarks and agenda
CEO welcomed stockholders, introduced key executives, legal counsel, and Inspector of Elections.
Meeting held pursuant to notice mailed to all stockholders of record.
Quorum established with 48.16% of outstanding voting stock present.
Specific resolutions to be voted on
Approval of an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-30, with the exact ratio to be set by the Board.
Board retains discretion to abandon the reverse stock split even if approved.
Approval of potential adjournment of the meeting to solicit more votes if needed.
Q&A with stakeholders
Opportunity provided for stockholders to ask questions before voting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from GRI Bio
- Lead candidate improved lung function and fibrosis biomarkers in IPF, with strong safety data.GRI
Corporate presentation16 Mar 2026 - Positive phase 2A IPF results and IND plans for lupus program signal strong pipeline momentum.GRI
Corporate Connect Webinar Series11 Feb 2026 - Strong cash position and positive clinical data support continued pipeline advancement.GRI
Q4 20254 Feb 2026 - Biopharma seeks up to $250M for immune therapies, advancing IPF and lupus programs amid high risk.GRI
Registration Filing30 Jan 2026 - Shareholders to vote on a reverse stock split to help maintain Nasdaq listing and flexibility.GRI
Proxy Filing29 Dec 2025 - Stockholders to vote on a reverse stock split to support Nasdaq compliance at a virtual meeting.GRI
Proxy Filing19 Dec 2025 - Registering 1.58M shares for resale from warrants, with proceeds only if warrants are exercised.GRI
Registration Filing16 Dec 2025 - H.C. Wainwright & Co. is exclusive underwriter, earning 7% fees and warrants, with no future right of first refusal.GRI
Registration Filing10 Dec 2025 - Biopharma seeks $8.6M to advance IPF and autoimmune drug pipeline amid financial and Nasdaq risks.GRI
Registration Filing8 Dec 2025